MaxCyte, Inc. (MXCT): Price and Financial Metrics

MaxCyte, Inc. (MXCT): $3.95

0.07 (+1.80%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

C

MXCT Price/Volume Stats

Current price $3.95 52-week high $5.55
Prev. close $3.88 52-week low $2.45
Day low $3.81 Volume 534,100
Day high $3.97 Avg. volume 636,075
50-day MA $4.33 Dividend yield N/A
200-day MA $4.19 Market Cap 412.36M

MXCT Stock Price Chart Interactive Chart >


MaxCyte, Inc. (MXCT) Company Bio


MaxCyte, Inc. operates as a cell-based therapies and life sciences company in the United States and internationally. Its transfection systems include MaxCyte STX, a scalable transfection system that uses flow electroporation technology for the engineering of cells for a range of applications; MaxCyte VLX, an instrument for large volume cell-engineering; and MaxCyte GT, a non-viral cell-engineering technology designed for clinical use. The company also provides single use sterile processing assemblies; and proprietary electroporation buffers; and ExPERT brand series of instruments and consumables, as well as insourcing services. In addition, it develops CARMA, a novel and proprietary technology for the development of non-viral, human messenger RNA-based, chimeric antigen receptor or T-cell receptor redirected immune cell therapies. The company licenses and sells its instruments and technology; and sells its products to drug developers and biopharmaceutical companies. It has a clinical and commercial license agreement with Allogene Therapeutics, Inc. The company was founded in 1998 and is headquartered in Gaithersburg, Maryland.


MXCT Latest News Stream


Event/Time News Detail
Loading, please wait...

MXCT Latest Social Stream


Loading social stream, please wait...

View Full MXCT Social Stream

Latest MXCT News From Around the Web

Below are the latest news stories about MAXCYTE INC that investors may wish to consider to help them evaluate MXCT as an investment opportunity.

Hedge Funds Say These Penny Stocks Are Poised to Explode

In this article, we will take a detailed look at hedge funds say these penny stocks are poised to explode. To see more such stocks, click Hedge Funds Say These 5 Penny Stocks are Poised to Explode. Despite common belief, not all penny stocks are inherently risky and suitable only for short-term gains. Some penny stocks […]

Yahoo | December 19, 2023

With 74% institutional ownership, MaxCyte, Inc. (LON:MXCT) is a favorite amongst the big guns

Key Insights Institutions' substantial holdings in MaxCyte implies that they have significant influence over the...

Yahoo | December 15, 2023

MaxCyte Announces CEO Transition and Updates Revenue Guidance for 2023

Doug Doerfler, President and CEO, to Retire Effective December 31, 2023; will continue to serve as an advisor to MaxCyte Maher Masoud, EVP, Head of Global Business Development and Chief Counsel, to Succeed Mr. Doerfler as President and CEO, Effective January 1, 2024 MaxCyte is reiterating 2023 expected core business revenue of $28-30 million, and the Company now expects to exceed prior SPL program-related guidance, with revenue of at least $10 million ROCKVILLE, Md., Dec. 11, 2023 (GLOBE NEWSWIR

Yahoo | December 11, 2023

Insider Sell Alert: President and CEO Douglas Doerfler Sells 124,450 Shares of MaxCyte Inc (MXCT)

MaxCyte Inc (NASDAQ:MXCT), a global cell-based therapies and life sciences company, has recently witnessed a significant insider sell by its President and CEO, Douglas Doerfler.

Yahoo | December 7, 2023

Insider Sell Alert: President and CEO Douglas Doerfler Sells 25,550 Shares of MaxCyte Inc (MXCT)

MaxCyte Inc (NASDAQ:MXCT), a global cell-based therapies and life sciences company, has recently witnessed a significant insider sell by its President and CEO, Douglas Doerfler.

Yahoo | December 2, 2023

Read More 'MXCT' Stories Here

MXCT Price Returns

1-mo -10.63%
3-mo -20.52%
6-mo 27.01%
1-year -21.78%
3-year N/A
5-year N/A
YTD -15.96%
2023 -13.92%
2022 -46.42%
2021 N/A
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!